corcept therapeutics just got an infusion of cash from the press release corcept therapeutics incorporated nasdaq cort today announced the completion of a private placement of , , shares of its common stock at a price of per share , pursuant to a definitive agreement entered into today with accredited investors the investors are led by paperboy ventures llc , who is currently a significant shareholder of corcept sutter hill ventures , alta partners , llp , venture capital firms that are currently significant shareholders in corcept , and members of the corcept board of directors , joseph c cook , jr , james a harper , david l mahoney , alan f schatzberg , m d and james n wilson , are also investors in addition , investors in this financing round included black point group , llp , vaughn bryson and daniel bradbury already a good short term investment , as the stock is now at a share if you 've read my prior writings about corcept , you can see that i'm highly skeptical about it 's main product , corlux mifepristone ru , which is aiming to treat psychotic depression although the company has tried to spin negative findings as actually being positive , it 's hard to see how a series of studies showing poor efficacy will lead to helping patients in any meaningful fashion might the latest influx of cash help out the corcept insiders who hold a major stake in the company ? sure conflicts of interest it appears that dr alan schatzberg bought , shares in the latest round of funding it has been reported previously that schatzberg has written quite positive comments about corlux in journals and some have questioned whether his financial stake in the company has skewed his judgment on the topic i want everyone to consider the following conundrum schatzberg holds about million shares of corcept currently so , if corlux bombs a clinical trial , is he going to a immediately report the negative results in a press release b move publishing the negative results in a scientific journal to the top of his to do list c spin the results in a very favorable fashion or make sure that someone who writes the press release and or scientific paper does so d just bury it entirely probably not an option with such a small company that likely announces most if not all of its trials beforehand if i was in a position where i had such a large financial stake , i 'd have a hell of a time doing a or b when large dollar amounts are at stake , it 's not easy to say , hey , this product does n't seem to work and watch your stock holdings evaporate this is why conflicts of interest are a problem some academic researchers really are just in it for the money i think they are a very small minority i bet that most researchers who end up with big time conflicts of interest start off thinking , hey , this could be a great new form of treatment for condition x then , hey , why not make some money while you 're doing god 's work , helping to heal people we 're an entrepreneurial society , so we tend to believe that people should be rewarded for having an enterprising spirit now , if the product turns out to not be so effective and or to have some unpleasant side effects , then look at the predicament here 's the conflict help people with condition x or help my own cash flow ? or say i'm a doctor who makes some good money on the side giving educational speeches to fellow physicians about a drug , say , zyprexa when i find out that said drug is linked to numerous health problems , do i bring that up in my speeches , knowing fully that such discussion is likely going to get me canned from the speaking circuit ? the list of potential examples could go on for days